Press Releases

Bionaturis Group grows through the acquisition of the company ZIP Solutions

Zera Intein Protein Solutions (ZIP) is specialized in the development of technologies for the production of peptides and recombinant proteins for both therapeutic and industrial interest, with applications in the biotechnological, pharmaceutical, veterinary and industrial sectors.
Both parties agreed as a mandatory irrevocably condition to trigger the transaction the event of signing a co-development and license agreement between ZIP and a leading multinational company, which occurred last April, 24. Under the terms of the agreement the multinational is granted a worldwide exclusive license for the final development and market of Splittera® technology for industrial purification of biological products.

The acquisition of this company, located in Barcelona and owned by Inveready Innvierte Biotech II, is valued at 1.6 million Euros

 

 May 3, 2016.  Bionaturis Group continues its expansion with the acquisition of the company Zera Intein Protein Solutions (ZIP), specialized in the development of technology for the production of peptides and recombinant proteins for application in the biotechnology, pharmaceutical, veterinary, and industrial sectors.

ZIP, founded in March 2015, inherited the main assets of Era Biotech, a company established in 2002 as a spin-off of the CSIC, in which approximately EUR 13 million were invested. ZIP, located in the Parc de Recerca in the Universitat Autònoma de Barcelona has a three people team and a rich portfolio of seven families of patents. The company commercializes its proprietary technologies Zera® and Splittera®, which facilitates the production and purification of difficult to express biological compounds and improve the production capacity of cellular systems. ZIP is owned by Inveready Innvierte Biotech II.

The acquisition of this company increases Bionaturis Group services portfolio and contributes to the international positioning as a partner of reference for the development of biological products for both human and animal […]

May 3rd, 2016|Blog english, Press Releases|Comments Off|

Biobide signs a contract with the U.S. National Institute of Environmental Health Sciences (NIH-NIEHS)

This project will analyze the toxicological impact of exposure to 30 chemical compounds using zebrafish as animal model.

The NIEHS is one of the 27 Institutes and Centers composing the US-National Institutes of Health.

January 25, 2016. BBD BioPhenix-Biobide (now part of Bionaturis Group), has recently signed a contract agreement with one of the U.S. National Institutes of Health, the National Institute of Environmental Health Sciences (NIH-NIEHS), for analyzing the impact of exposure to different chemicals with unknown toxicological potential in zebrafish embryos. Biobide provides zebrafish-based services in the preclinical area, mainly toxicology, through early detection of adverse effects in a Good Laboratory Practice (GLP) setting.

Biobide will perform the assessment of bioavailability and toxicity in zebrafish embryos following exposure to 30 compounds with potential for various adverse effects, providing high content screening information on multiple target organs using a GLP-environment.

This contract agreement between Biobide and one of the main Institutions of Public Health in the USA, the NIH, is the result of years of preparation and study. BBD BioPhenix-Biobide, is one of the recognized zebrafish resource institutions worldwide. “This contract agreement becomes relevant because it may facilitate future collaborations with this prestigious institution”, the R&D Management Director at the company, Arantza Muriana, has stated.

The collaboration between Biobide and the NIH-NIEHS started last year when they collaborated in a project to study the toxicity of several flame retardants found in everyday household products, such as utensils, upholstery and furniture, to which people, and most importantly babies and young children, are regularly exposed.  Biobide and the NIH-NIEHS utilized the versatility of the zebrafish model to evaluate the toxicity of environmental compounds with the main goal of the assay being the reduction or prevention of the use of such […]

January 25th, 2016|Blog english, Press Releases|Comments Off|

Bionaturis Group takes part in the BIOMAP project

BIOMAP is a consortium led by Laboratories Rovy  that includes Vivacell Biotechnology Spain, Vaxdyn,  and Bionaturis
The Feder-Interconecta Programme, via the Centre for the Development of Industrial Technology (CDTI, in Spanish), has granted Bionaturis 572.988€ for this biomedicine development initiative.

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the BIOMAP consortium, devoted to the multivariate design of assays, with the ultimate goal of developing biomedicines using the pharmaceutical criteria for quality, security and efficacy designs (Quality by design or QbD).

The QbD method will be applied to the candidate selection processes for the development portfolio of each company in the consortium, reducing time and optimizing the process. In addition, these innovations aim to position the companies both technologically and commercially by providing the market with the scale-up system for structurally complex and highly-powerful biologics that will be both time and cost competitive.

The BIOMAP consortium is led by Laboratories Rovi and includes Vaxdyn, Vivacell Biotechnology Spain, and Bionaturis. In particular, Bionaturis will receive an incentive of 572.988€ granted by the CDTI from the Feder-Interconecta Programme, with the support of the Ministry of Economy and Competitiveness.

About Bionaturis

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

www.bionaturis.com

TO DOWNLOAD THE PRESS RELEASE, PLEASE, CLICK HERE

 

For further information:

Bionaturis Press

Virginia Montero

+34 856 818 424 / 655 311047

press@bionaturis.com

 

Disclaimer

The Market and investors are informed that the Company’s new developments are subject to significant risks and uncertainties, that include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate […]

January 12th, 2016|Blog english, Press Releases|Comments Off|

Bionaturis Group takes part in the development of a vaccine against cervical cancer

The Centre for the Development of Industrial Technology (CDTI, in Spanish) has granted an incentive of 184.847,40 Euros to the company from the European Programme Eurostars
The project is led by the German company BioEnergy GmbH & Consultant with participation from the German Cancer Research Center

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the development of a cost-effective and possibly oral vaccine against cervical cancer. The initiative, led by the German company BioEnergy GmbH & Consultant with the participation of the German Cancer Research Center, receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

According to the World Health Organization (WHO), developing countries suffer the highest impact from cervical cancer, which is caused by the Human Papillomavirus (HPV). Currently available vaccines are at a price point that makes them unaffordable for most people in developing countries. In addition to the loss of human lives, this circumstance leaves a large gap in the global coverage against the disease. With this project, Bionaturis Group is taking part in an alternative strategy to produce a cost-effective vaccine that will be affordable for the most highly impacted regions, following its vision of ‘A Global Access To Health’.

“This project is a real and relevant challenge for Bionaturis because, with it, we are expanding our horizons. Our acquired technological expertise in both vaccine development and cost effective manufacturing platforms lets us face this initiative with the realistic goal of providing to the population at risk a first-in-class drug that will be affordable given the social and economic conditions of their countries”, Bionaturis CSO, Juan Jose Infante, has stated.

The WHO highlights that cervical cancer caused […]

January 12th, 2016|Blog english, Press Releases|Comments Off|

Bionaturis unveils the development of six new biotech products

Five of these new drugs point to Animal Health sector that represents a $100 billion global annual worldwide market

According to “Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2020” report (by  P&S Market Research) around $29 billion were assigned to pharmaceutical products, feed additives and vaccines in 2014.

The same report forecasts for this segment up to $44 billion by 2020, with a CAGR of 7.0%

The population growth and standard of living, resulting on a higher consumption of milk and meat and an increasing trend of adopting pets are some of the main robust drivers for the growth of the Animal Health market, which has nowadays a booming demand on both biological products and compounds devoted to reduce the use of traditional antibiotics

Broadening its portfolio Bionaturis Group strengthens its position as a reference partner to develop biological products for animal health from livestock to pets, having presence in the main markets at geographic, species and diseases level

 

Jerez de la Frontera, October 6th 2015. Bionaturis Group (ticker BNT) has recently unveiled up to six new biotech developments broadening its products portfolio, now accounting for more than twenty compounds in different developing stages for both human and animal health.

Five of these new products are devoted to veterinarian sector, pointing to several high-relevance diseases in livestock and pets, such as atopic dermatitis, osteoarthritis (or arthrosis) and different types of cancer, enhancing the Group position as a benchmark partner in the development of biological products for animal health.

The new unveiled products are:

Lead

Description

Indication

Specie

Stage

BNT014
Tailored universal VLP-vaccine
Prevention of common cold (rhinovirus)
Humans
Proof of concept in vivo

BNT015
Recombinant VPL Vaccine
Viral infection
Swine
Proof of concept in vivo

BNT018
Recombinant VPL Vaccine
Rabbit Hemorrhagic Fever
Rabits
Proof of concept in vivo

BNT020
Feline recombinant interferon omega (bio-better)
Antiviral, antiproliferative, immunomodulatory
Dogs and cats
Proof […]

October 6th, 2015|Blog english, Press Releases|Comments Off|

Corporacion Tecnologica de Andalucia supports Bionaturis in the development of a project on animal health

The initiative Bovihealth aims the development of peptides to be used as health and growth promoter in cattle.

Besides Bionaturis Group, Bovihealth also has the Sociedad Cooperativa Andaluza Ganadera del Valle de los Pedroches (COVAP) as a partner.

 

Jerez de la Frontera, 24st of July, 2015. Corporacion Tecnologica de Andalucia (CTA) has granted the Company with an incentive worth of €147.027,46 to partially fund the Bovihealth project. The initiative aims the development of peptides to be used as health and growth promoter in cattle. The Company partners up in this project with an end-user of the seek products, the Cooperativa del Valle de los Pedroches (COVAP). The incentive is completely subsidized by the Regional Andalusian Government and the Ministry of Economy and Competitiveness of Spain.

“With this initiative we intend to develop effective feeding treatments to boost the immune system of the cattle herd, improving the productivity index at the same time” explains Victor Infante, CEO of Bionaturis Group. “The approach points to reduce the use of traditional antibiotics as far as possible. To that end, we will test some peptides with proven successful activity in other type of livestock (swine, poultry)”

Two public research groups, the group BIO 155 of Analysis of biological macromolecules of interest in biomedicine, which belongs to the CSIC-Instituto López-Neyra, and the group AGR 137 of Animal Anatomical Pathology, of the University of Córdoba (UCO) also collaborate in the project.

About CTA

Corporacion Tecnologica de Andalucia is a private foundation, launched by the Junta of Andalusia and backed by 152 member companies, in order to promote regional innovation on the basis of transference. CTA is dedicated to financing R&D business projects in collaboration with Universities, and offers added services to innovative companies, universities, technological centers […]

July 24th, 2015|Blog english, Press Releases|Comments Off|

Bionaturis signs a strategic agreement for its corporate expansion in China

As part of the agreement, Bionaturis Group will establish its first subsidiary company in China in the new technological area of Changshu (Jiangsu).

The new technological and industrial area of Changshu has been the one which has relied most on hosting the Spanish biotechnological group.

Bionaturis’ system for the development of biological medicinal products, known as Flylife, will serve as a baseline for the project.

Jerez de la Frontera, July 2nd 2015. Bionaturis Group and the Administrative Committee of Changshu New & Hi-Tech Industrial Development Zone –CNZ- (Jiangsu) – have signed a strategic agreement to host a subsidiary company of the biotechnological Spanish group, which will serve to develop and allocate biotechnological products in the Asian market.

As part of the agreement, within the park Bionaturis Group will have cutting-edge facilities in order to carry out its activities, as well as a diversity of direct incentive programs. In a first phase, facilities of 600 meters squared have been set out, which include a laboratory area and an administrative one. The laboratory area will host, among other services, Bionaturis’ biological medical production system, known as Flylife, and its capacity to develop state-of-the-art vaccines for human and animal health. In the new subsidiary company, the Spanish Group will also have a development department as well as a commercial office.

Currently, Bionaturis Group develops, at different stages, a variety of medicines intended for human health, as well as veterinary products that act or prevent habitual diseases in livestock (poultry, pigs, cattle…), farmed fish and pet animals.

Victor Infante, Chief Executive of Bionaturis Group, believes that “China is and will increasingly be one of the main markets in human and animal health. The commitment of Changshu’s authorities to host Bionaturis Group is a proof […]

July 2nd, 2015|Blog english, Press Releases|Comments Off|

Bionaturis and the US-Biotech company BMI sign an agreement for the jointly development of human and animal vaccines

The goal of this strategic partnership is to join forces to bring to market new and improved biopharmeutical products.

As the first step of this agreement, Bionaturis Group will support the manufacturing development of a first-in-class vaccine to prevent the human common cold.

 

Jerez, June 18th 2015. Bionaturis Group and Biological Mimetics, Inc., -BMI- (based in Maryland, USA) has started a new strategic collaboration agreement to jointly develop new vaccines for human and animal health applications.

In the context of this agreement Bionaturis Group will use its proprietary FLYLIFE platform for the production of experimental batches of vaccines designed using BMI’s Immune Refocusing Technology (IRT). Specifically, as part of the agreement, Bionaturis Group has begun the works corresponding to the manufacturing proof of concept of a candidate of BMI of a first in man vaccine against Human Rhinovirus, the cause of the common cold as well as primary infant viral pneumonia and its known associations with asthma.

According to the National Center of Health, in the United States there are around 62 million cases annually of common cold with human rhinovirus infection being the culprit for about 35% of them. There are over 100 different types of rhinoviruses, which makes developing a vaccine against rhinoviruses difficult. According to experts, the economic consequences of absenteeism from work, school and primary care services caused by the common cold have an impact, only in the United States economy, between 35 and 40 billion US dollars a year.

The lead of BMI is designed to become the first in man cross serotype vaccine on the market to prevent and/or limit clinical complications from infection. The vaccine is to undergo preclinical and process development and evaluation, carrying out safety, immunogenicity and efficacy trials using […]

June 18th, 2015|Blog english, Press Releases|Comments Off|

Bionaturis launches today its capital increase

The negotiation period is between 9th until 15th June, both inclusive
The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

Jerez, June 9th 2015. The Board of Directors of Bolsas y Mercados Españoles (BME) has agreed the listing from today Tuesday and until next Monday, June 15th, both inclusive, 4.633.036 preferential subscription rights of the Bionaturis Group that will be negotiated in the Alternative Equity Market (MAB) under the code (BNT.D).

The rights negotiation of the new Bionaturis shares falls within the subscription period, which is scheduled4th July to be over. Once completed it and if there is any shares left, discretionary assignment period will be open to place the remaining shares to other investors.

This capital increase, approved last week by the governing body of the MAB, aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share. If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a […]

June 9th, 2015|Blog english, Press Releases|Comments Off|

Approved the Bionaturis Group Capital Increase for a maximun of up to 579.129 new shares

The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

After the acquisition Bionaturis Group would have a global turnover over €8 Million in the year 2016, with an EBITDA’s operating margin about 30% and employing more than 60 workers, strengthening the Group’s industrial structure.

The Company carried out another capital increase operation last April 2014 for an amount worth of €3 Million with 76% of oversubscription.

Jerez, on June 2, 2015. The Alternative Equity Market (MAB) Governing Body has approved the Document of Capital Increase (Spanish DAM) presented by Bionaturis Group in order to formalize the capital increase operation authorized by its Board of Directors last May, 14 2015. This capital increase aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share.

If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a par value of €0,05 each one.

The new issued shares will trade in MAB as soon as […]

June 2nd, 2015|Blog english, Press Releases|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR